stockrow
Saturday 7 November 2026
Export GHRS’s income statement to Excel — free account
GH Research PLC
GHRS Healthcare Biotechnology
- EPS
- −53.3%
- Free cash flow
- −66.6%
- Total debt
- −97.9%
Quarter to June 2026, against a year earlier
18.49
0.05
+0.27%
Follow GHRS
Alert me
GH Research PLC (GHRS) P/E ratio
GH Research PLC has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NKTR Nektar Therapeutics compare | n/m |
| DRTS Alpha Tau Medical Ltd. compare | n/m |
| TSHA Taysha Gene Therapies, Inc. compare | n/m |
| URGN Urogen Pharma compare | n/m |
| SLN Silence Therapeutics PLC Sponsored ADR compare | n/m |
| GHRS GH Research PLC | n/m |
| LBRX LB Pharmaceuticals Inc compare | n/m |
| KARD KARDIGAN INC compare | n/m |
| OMER Omeros Corporation compare | 9.8× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)